Payment overview · 2025
General Payments
$14.41
1 reported records · 1 companies
Healthcare provider profile · identity verified
Andrew Daluga, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENFIELD, IN · NPI 1790103315
Verified facts
What the public records show
CMS Open Payments records show Andrew Daluga, M.D. received $14.41 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.41 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.41 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
59 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 129 |
| Losartan Potassium | Losartan Potassium | 327 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 74 |
| Lisinopril | Lisinopril | 272 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 72 |
| Metformin Hcl | Metformin Hcl | 207 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 46 |
| Gabapentin | Gabapentin | 181 | 45 |
| Meloxicam | Meloxicam | 168 | 32 |
| Omeprazole | Omeprazole | 167 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 44 |
| Simvastatin | Simvastatin | 155 | 45 |
| Furosemide | Furosemide | 134 | 43 |
| Allopurinol | Allopurinol | 103 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 25 |
| Ozempic | Semaglutide | 93 | 20 |
| Celecoxib | Celecoxib | 90 | 25 |
| Eliquis | Apixaban | 90 | 19 |
| Mounjaro | Tirzepatide | 88 | 19 |
| Glimepiride | Glimepiride | 85 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 18 |
| Metformin Hcl Er | Metformin Hcl | 74 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 14 |
| Trazodone Hcl | Trazodone Hcl | 70 | 17 |
| Donepezil Hcl | Donepezil Hcl | 64 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 15 |
| Montelukast Sodium | Montelukast Sodium | 63 | 18 |
| Bupropion Xl | Bupropion Hcl | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 61 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 12 |
| Sertraline Hcl | Sertraline Hcl | 60 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 59 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Potassium Chloride | Potassium Chloride | 56 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Atenolol | Atenolol | 51 | 14 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 15 |
| Spironolactone | Spironolactone | 51 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Jardiance | Empagliflozin | 49 | 14 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Carvedilol | Carvedilol | 48 | 11 |
| Prednisone | Prednisone | 48 | 41 |
| Chlorthalidone | Chlorthalidone | 47 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 16 |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Finasteride | Finasteride | 43 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 13 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 16 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Valsartan | Valsartan | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.41 · 1 records | GlaxoSmithKline, LLC. | SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error